IL1RL1 gene variations are associated with asthma exacerbations in children and adolescents using inhaled corticosteroids

TY - JOUR

T1 - IL1RL1 gene variations are associated with asthma exacerbations in children and adolescents using inhaled corticosteroids

AU - Dijk, F. Nicole

AU - Vijverberg, Susanne J.

AU - Hernandez-Pacheco, Natalia

AU - Repnik, Katja

AU - Karimi, Leila

AU - Mitratza, Marianna

AU - Farzan, Niloufar

AU - Nawijn, Martijn C.

AU - Burchard, Esteban G.

AU - Engelkes, Marjolein

AU - Verhamme, Katia M.

AU - Potočnik, Uroš

AU - Pino-Yanes, Maria

AU - Postma, Dirkje S.

AU - Maitland-van der Zee, Anke Hilse

AU - Koppelman, Gerard H.

N1 - Funding Information: We would like to thank the participants and their parents of the studied cohorts for their participation. We also would like to acknowledge the field workers, data managers, and scientific collaborators dedicated to these cohorts. The authors acknowledge the GALA II and SAGE investigators (Kelley Meade, Harold J. Farber, Pedro C. Avila, Denise Serebrisky, Shannon M. Thyne, Emerita Brigino-Buenaventura, William Rodriguez-Cintron, Saunak Sen, Rajesh Kumar, Michael Lenoir, Luisa N. Borrell, and Jose R. Rodriguez-Santana), the recruiters, participants, and the study coordinator Sandra Salazar. We thank as well the ESTATe investigators (Pharmo: Ron Herings, Annemarie Janse, Jettie Overbeek, Josine Kuiper. IPCI: Katia Verhamme, Hettie Janssens, Johan de Jongste, Miriam Sturkenboom). Funding Information: N. Hernandez‐Pacheco received a grant from Instituto de Salud Carlos III (ISCIII) and was co‐funded by the European Social Funds from the European Union (ESF) “ESF invests in your future.” MC Nawijn received a grant from GSK during the conduct of this study and outside the submitted work. ME Engelkes received a grant from Zonmw. K. M. Verhamme received a grant from ZonMw and she works for a research group who in the past received unconditional grants from: Yamanouchi, Pfizer/Boehringer Ingelheim, Novartis and GSK. M Pino‐Yanes received a grant from the Spanish Ministry of Economy, Industry and Competitiveness and a grant from Instituto de Salud Carlos III (ISCIII). AH Maitland‐van der Zee received an unrestricted research grant from GSK, and Boehringer Ingelheim. She also received a grant from ERANET ERACOSYSMED, and she participated in an advisory board for Astra Zeneca. DS Postma declares that the University of Groningen has received money for DS Postma regarding a grant for research from Astra Zeneca, Chiesi, Genentec, GSK and Roche. Fees for consultancies were given to the University of Groningen by Astra Zeneca, Chiesi, and GSK. GH Koppelman received grants from the Lung Foundation of the Netherlands, the Ubbo Emmius Foundation, during the conduct of the study; and he received grants from Lung Foundation of the Netherlands, GSK, Tetri Foundation, Vertex, TEVA the Netherlands, outside the submitted work. GHK participated in an advisory board meeting of GSK. The rest of the authors declare that they have no relevant conflict of interests. Funding Information: The PACMAN study was supported by an unrestricted grant from GlaxoSmithKline (GSK), whereas genetic analysis for the present study was supported by a Lung Foundation of the Netherlands grant no. AF3.2.09.081JU. FND was supported by the Ubbo Emmius Foundation. The GALA II and SAGE studies were funded by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, National Institutes of Health (1R01HL117004, R01Hl128439, R01HL135156, and 1X01HL134589), National Institute of Health and Environmental Health Sciences (R01ES015794 and R21ES24844), the National Institute on Minority Health and Health Disparities (1P60MD006902, U54MD009523, and 1R01MD010443), and the Tobacco‐Related Disease Research Program under Award Number 24RT‐0025 to EGB. This work was also funded by Instituto de Salud Carlos III (AC15/00015), through Strategic action for Health Research (AES) and European Community (EC) within the Active and Assisted Living (ALL) Programme framework,  and by the SysPharmPedia grant  from the ERACoSysMed first joint Transnational cCall from the European Union under the Horizon 2020. NH‐P was funded by a fellowship (FI16/00136) from Instituto de Salud Carlos III (ISCIII) and co‐funded by the European Social Funds from the European Union (ESF) “ESF invests in your future” and MP‐Y was supported by the Ramón y Cajal Program (RYC‐2015‐17205) by the Spanish Ministry of Economy, Industry, and Competitiveness. For the SLOVENIA study, the authors acknowledge the financial support from the Slovenian Research Agency (research core funding No. P3‐0067) and from SysPharmPedia grant, co‐financed by Ministry of Education, Science and Sport of the Republic of Slovenia. The ESTATe project was supported by a ZonMw Grant No 113201006. The PiCA study was overall supported by ERACoSysMed 1st Joint Transnational Call (SysPharmPedia).

PY - 2020/4/1

Y1 - 2020/4/1

UR - https://www.scopus.com/pages/publications/85076766693

U2 - 10.1111/all.14125

DO - 10.1111/all.14125

M3 - Comment/Letter to the editor

C2 - 31755552

AN - SCOPUS:85076766693

SN - 0105-4538

VL - 75

SP - 984

EP - 989

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 4

ER -